Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH (CandLE)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00607633
First received: January 23, 2008
Last updated: February 5, 2008
Last verified: January 2008

January 23, 2008
February 5, 2008
January 2007
Not Provided
to estimate under naturalistic conditions the impact of the antihypertensive therapy with candesartan or candesartan/HCT on pre-post change from Visit 1 to Visit 2 of Sokolow-Lyon index, Cornell index and Left Ventricular Mass Index. [ Time Frame: app. 3 monthly ]
Same as current
Complete list of historical versions of study NCT00607633 on ClinicalTrials.gov Archive Site
  • to estimate the change of the systolic and diastolic blood pressure, separately by the (maximum) prescribed daily dose of candesartan or candesartan/ HCT [ Time Frame: app. 3 monthly ]
  • to gain further insight into the occurrence of unknown, unexpected and/or rarely occurring adverse events (AE) by estimating the incidence under naturalistic conditions. [ Time Frame: app. 3 monthly ]
Same as current
Not Provided
Not Provided
 
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Essential Hypertension and a Concomitant Disease Left Ventricular Hypertrophy

The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the impact of the antihypertensive therapy with candesartan or candesartan/HCT on relevant medical parameters related to the left ventricular hypertrophy (LVH) as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension..

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Ambulant patient

  • Essential Hypertension
  • Left Ventricular Hypertrophy
Not Provided
1
Patient with essential hypertension and LVH under treatment with candesartan or candesartan HCT
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
686
October 2007
Not Provided

Inclusion Criteria:

  • essential hypertension
  • left ventricular hypertrophy
  • under candesartan treatment

Exclusion Criteria:

Not Provided
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00607633
NIS-CGE-ATA-2007/2
No
Andrea Pahor, AstraZeneca Germany
AstraZeneca
Not Provided
Principal Investigator: F. Sonntag, MD Cardiologist, Henstedt-Ulzburg
Study Chair: Andrea Pahor, MD MED Dep., AstraZeneca Germany
AstraZeneca
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP